Rare Disease Research, LLC | Atlanta, GA
Status and phase
Conditions
Treatments
About
PRIZM is a Phase 2b randomized, double-blind, placebo-controlled, 3-treatment, 2-period, crossover study evaluating the efficacy and safety of oral zagociguat 15 and 30 mg vs. placebo when administered daily for 12 weeks in participants with genetically and phenotypically defined MELAS.
Full description
The goal of this clinical trial is to learn about the effectiveness of zagociguat in patients with MELAS. The main questions it aims to answer are:
The PRIZM study is evaluating 2 dose levels of zagociguat in a crossover design consisting of two 12-week treatment periods separated by a 4-week washout. Patients will be screened and if eligible, randomly assigned either to receive placebo in period 1 followed by active drug in period 2 OR to receive active drug in period 1 followed by placebo in period 2. Study medication is a once daily oral tablet and will be provided at the clinic and/or shipped to the participant's home. Clinic visits will occur at screening and Week 1 and Week 12 of each treatment period. Visits at Week 4 and Week 8 of both crossover periods will either be in clinic or optionally at the participant's home. Study assessments will be conducted weekly on a phone app and a separate tablet and additional assessments will be conducted during visits. Patients who complete the study will be eligible for an open label extension study.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Signed consent form.
18 to 75 years of age.
Diagnosed with MELAS based on the presence of each of the following criteria:
Scores below normal average on composite memory score from One Back and One Card Learning tests.
Reports fatigue due to MELAS.
Can complete at least 1 sit-to-stand in the 30-second test interval.
Completes all at-home weekly activities independently during the Screening Period (caregiver may help set up device/app, log-in, etc.).
Other criteria per the protocol.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
44 participants in 4 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal